Disability Status and Quality of Life in Iraqi Patients with Multiple Sclerosis; an Observational Study
DOI:
https://doi.org/10.32947/ajps.v26i1.1375Keywords:
Multiple sclerosis, Disability, Expanded Disability Status Scale (EDSS), Multiple Sclerosis Quality of Life-29 (MSQoL-29)Abstract
Background: Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system and a major non-traumatic disabling in young adults. Disability adversely affects quality of life, daily activities, and psychological abilities, reducing independence. Therefore, evaluating disability and quality of life is essential to understand the disease burden.
Aim: To evaluate the level of disability and its association with health-related quality of life, and to identify sociodemographic and clinical factors associated with both outcomes in Iraqi patients with multiple sclerosis.
Methods: A cross-sectional study was conducted at the Multiple Sclerosis consultation clinic, Baghdad Medical City. A total of 150 patients with multiple sclerosis were enrolled. Health-related quality of life was assessed using the multiple sclerosis quality of life-29 questionnaire, and disability was evaluated using the Expanded Disability Status Scale (EDSS).
Results: Relapsing-remitting multiple sclerosis was observed in 86%. The median Expanded Disability Status Scale (EDSS) among multiple sclerosis patients was 4.5 indicating a moderate level of neurological disability. EDSS showed significant negative correlations with the physical health composite (r = − 0.705, P < 0.001) and the mental health composite (r = − 0.481, P < 0.001) each combining multiple domains of the MSQoL-29.
Conclusion: Higher neurological disability is associated with lower quality of life in patients, and the impact is more pronounced on the physical side than the mental. This finding indicates that physical disability alone may not fully capture the overall impact of the disease.
References
1- Jasim RZ. Multiple Sclerosis is a Risk Factor for Hyperthyroidism and Interferon Beta Action on Thyroid Hormones via Novel Immuno-neuro-enzymological Mechanisms. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2020;20(4):72-81.
2- Walter E, Traunfellner M, Meyer F, Enzinger C, Guger M, Bsteh C, et al. Cost-effectiveness of the Floodlight® MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis. Digital health. 2025;11:20552076251314550.
3- Abbas RS, Abdulridha MK, Shafek MA. Clinical evaluation of potential anti-inflammatory effect of Vitamin D3 adjuvant therapy for chronic asthma in iraqi patients. Int J Pharm Pharm Sci. 2017;9(1):139-44.
4- Daoud AG, Waheed HJ, Abdala ME. The Impact of Vitamin D on The Development of Multiple Sclerosis. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2021;21(3):7-15.
5- Yahya AA, Abdulridha MK, Al-Rubuyae BJ, Al-Atar HA. The effect of vitamin D and co-enzyme Q10 replacement therapy on hormonal profile and ovulation statusin women with clomiphene citrate resistant polycystic ovary syndrome. Journal of Pharmaceutical Sciences and Research. 2019;11(1):208-15.
6- Hassoun HK, Al-Mahadawi A, Sheaheed NM, Sami SM, Jamal A, Allebban Z. Epidemiology of multiple sclerosis in Iraq: retrospective review of 4355 cases and literature review. Neurological research. 2022;44(1):14-23.
7- Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147-61.
8- Kołtuniuk A, Pawlak B, Krówczyńska D, Chojdak-Łukasiewicz J. The quality of life in patients with multiple sclerosis–Association with depressive symptoms and physical disability: A prospective and observational study. Frontiers in psychology. 2023;13:1068421.
9- Siahvashi MM, Shamsizadeh M, Tapak L, Ghiasian M, Azizi A. Comparison of the effects of nursing and peer education on quality of life and resilience in patients with multiple sclerosis: A randomized clinical trial. Heliyon. 2024;10(20).
10- Sotoudeh S, Maroufizadeh S, Rouhi Balasi L, Esfandiari A, Nouri A, Bakhtiari F. Quality of life and its predictors in patients with multiple sclerosis. Jundishapur J Chronic Disease Care. 2023;13(1):e138840.
11- Rezapour A, Kia AA, Goodarzi S, Hasoumi M, Motlagh SN, Vahedi S. The impact of disease characteristics on multiple sclerosis patients’ quality of life. Epidemiology and health. 2017;39:e2017008.
12- Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology. 2011;69(2):292-302.
13- Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17(2):162-73.
14- Munaf ZA, Mohammed SI, Al-Gawwam GAAS. Impact of clinical pharmacist-led interventions on short term quality of life among multiple sclerosis patients taking disease-modifying therapy. Iraqi Journal of Pharmaceutical Sciences. 2025;34(1):256-65.
15- Vickrey B, Hays R, Harooni R, Myers L, Ellison G. A health-related quality of life measure for multiple sclerosis. Quality of life research. 1995;4(3):187-206.
16- Rosato R, Testa S, Bertolotto A, Confalonieri P, Patti F, Lugaresi A, et al. Development of a short version of MSQOL-54 using factor analysis and item response theory. PLoS One. 2016;11(4):e0153466.
17- Ziaie S, Namazi N, Afzal G, Barati S, Mohebbi R, Mir M, et al. Assessing multiple sclerosis-related quality of life among Iranian patients using the MSQOL-54 tool: a cross-sectional study. BMC neurology. 2021;21(1):333.
18- Kurtzke JF. Neurologic impairment in multiple sclerosis and the disability status scale. Acta neurologica scandinavica. 1970;46(4‐5):493-512.
19- Fogarty E, Walsh C, McGuigan C, Tubridy N, Barry M. Direct and indirect economic consequences of multiple sclerosis in Ireland. Applied health economics and health policy. 2014;12:635-45.
20- Portaccio E, Amato MP. Cognitive impairment in multiple sclerosis: an update on assessment and management. NeuroSci. 2022;3(4):667-76.
21- Moreno-Torres I, Sabín-Muñoz J, García-Merino A. Multiple sclerosis: epidemiology, genetics, symptoms, and unmet needs. 2019.
22- Vergani VE, Silveira BR, Cardoso GSME, Faber J, Bichuetti DB. The impact of multiple sclerosis on wellbeing, productivity, and societal relations. Arquivos de Neuro-Psiquiatria. 2025;83(5).
23- Ponzio M, Tacchino A, Verri A, Battaglia MA, Brichetto G, Podda J. Profile and burden of the family caregiver: the caring experience in multiple sclerosis. An observational study. BMC psychology. 2024;12(1):173.
24- Albelo-Martínez M, Rizvi S. Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies. Neurotherapeutics. 2025:e00601.
25- Dahlke F, Arnold DL, Aarden P, Ganjgahi H, Häring DA, Čuklina J, et al. Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO. MS cohort): Age is a key contributor to presentation. Multiple Sclerosis Journal. 2021;27(13):2062-76.
26- Skattebøl L, Nygaard GO, Leonardsen EH, Kaufmann T, Moridi T, Stawiarz L, et al. Brain age in multiple sclerosis: a study with deep learning and traditional machine learning. Brain Communications. 2025;7(3):fcaf152.
27- Lynch S, Baker S, Nashatizadeh M, Thuringer A, Thelen J, Bruce J. Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians? Multiple sclerosis and related disorders. 2021;49:102724.
28- Alharbi A. Assessment of Quality of Life and Fatigue in Patients with Multiple Sclerosis-A Cross-Sectional Study. Journal of Pioneering Medical Sciences. 2025;14:440-8.
29- HJ M. Quality of life and mental status of patients with multiple sclerosis-City of Mosul, Iraq. Teikyo Medical Journal. 2021;44(6):2901-8.
30- Aparicio-Castro E, Candeliere-Merlicco A, Santa C, Villaverde-González R. Association of depression in multiple sclerosis with fatigue, sleep disturbances, disability, and health-related quality of life: Outcomes of a cross-sectional study. Neurology Perspectives. 2025;5(1):100181.
31- El Harchaoui I, Abderemane A, Yahyaoui M, Ahami A. Exploring the relationship between economic status, quality of life and anxiety among Moroccan patients with multiple sclerosis.
32- Dahham J, Hiligsmann M, Kremer I, Khoury SJ, Darwish H, Hosseini H, et al. Health-related quality of life and utilities among Lebanese patients with Multiple Sclerosis: A cross-sectional study. Multiple Sclerosis and Related Disorders. 2024;86:105635.
33- Yalachkov Y, Soydaş D, Bergmann J, Frisch S, Behrens M, Foerch C, et al. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Multiple sclerosis and related disorders. 2019;30:33-7.
34- Glanz BI, Zurawski J, Gonzalez CT, Shamah R, Ratajska A, Chitnis T, et al. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders. 2020;40:101944.
35- Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, et al. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Multiple Sclerosis Journal. 2023;29(14):1808-18.
36- Krokavcova M, van Dijk J, Rosenberger J, Nagyova I, Gavelova M, Middel B, et al. The importance of depression and anxiety for perceived health status in younger and older patients with multiple sclerosis5.
37- Majerníková Ľ, Obročníková A, Hudáková A, Halász BG. Validation of the multiple sclerosis quality of life questionnaire-54 in Slovakia. Health Problems of Civilization. 2024;18(1).
38- Strijbis EM, Repovic P, Mostert J, Bowen JD, Uitdehaag BM, Cutter G, et al. The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. Multiple Sclerosis Journal. 2022;28(10):1606-19.
39- Özben S AA. The Prevalence and Impact of Insomnia in Multiple Sclerosis. Turkish Journal of Sleep Medicine. 2025.
40- Yalachkov Y, Soydaş D, Bergmann J, Frisch S, Behrens M, Foerch C, et al.Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.
41- Kołtuniuk A, Niezgoda K, Papierkowska R, Radzimska O, Bizoń A, Żurawska-Płaksej E, Chojdak-Łukasiewicz J. Quality of life among patients with multiple sclerosis: association with disease acceptance, optimism, and health-promoting behaviors. Scientific Reports. 2025 Aug 25;15(1):31174.
42- Cohen J. Statistical power analysis for the behavioral sciences: routledge; 2013.
43- Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses. Behavior research methods. 2009;41(4):1149-60.
44- Msheik A, Al Mokdad Z, Hmede R, Atat R. Advances in the understanding and management of multiple sclerosis phenotypes. Health Sciences Review. 2025 Sep 1; 16:100232.
45- Arteaga-Noriega A, Jose ZB, Johanna GV, John-Camilo GU, Fernando RG, Manuela RB. Factors associated with the progression of disability (EDSS) among MS patients. eNeurologicalSci. 2025 Dec 18:100602.
46- Bose G, Greene N, Healy BC, Weiner HL, Farnett L, Higuchi K, Babu EM, Chitnis T. Characteristics of People with Multiple Sclerosis by Phenotype Based on Cross-Sectional Analysis Using the CLIMB Study in the United States.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Fatima Moufeed Hassan Al Safar, Mohammed Mahmood Mohammed, Gheyath Abd Ali Shallal Al-Gawwam
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
